The first veterinary hospital in Sebastian to perform in-house stem cell therapy has helped two dogs suffering from osteoarthritis. Stem cell procedures were conducted one month ago by veterinarian Marcus Kramer of Highlands Animal Hospital on Toby, a 6-year-old golden retriever, and Oreo, 10, a border collie mix Continue reading
Cell therapy demonstrates high rate of complete closure of hard-to-heal wounds, including diabetic foot (DFU) and venous ulcers. Macrocure, a biotechnology company developing and selling advanced cell therapy products, announced today it has achieved positive results for a Real Life Phase IV trial of its lead product, CureXcell, for the treatment of hard-to-heal ulcers in a community care setting. The recently-completed trial aimed to evaluate the safety and efficacy of CureXcell for a variety of hard-to-heal ulcers and was conducted in 131 subjects at seven different clinics at the Clalit Heath Service facilities, Israel’s largest HMO. Continue reading
Shares of stem cell therapy developer Osiris Therapeutics Inc. Continue reading
SILVER SPRING, Md.–(BUSINESS WIRE)– Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, reports the Chairman of its associate company, SG Austria, Dr. Walter Gunzburg, participated in multiple private meetings with leading Japanese biotech and pharmaceutical companies following the recent Annual Meeting of the Organisation for Oncology and Translational Research (OOTR), where he was a invited guest speaker. Continue reading
LEUVEN, BELGIUM–(Marketwire -05/08/12)- TiGenix (TIG), a leader in the field of cell therapy, announced today that during the months of May and June the company will present at a number of key events in Europe and the U.S. geared at investor, industry, and academic audiences to highlight the commercial potential of ChondroCelect, the only approved cell therapy in Europe, and of the company’s innovative proprietary allogeneic stem cell platform with programs in Phase I, II, and III for a range of inflammatory and autoimmune diseases. May 15-16 BioEquity, Marriott Hotel, Frankfurt, Germany Presenter: Eduardo Bravo, CEO Date & time: Tuesday, May 15, 16:00-16:25 Room: Level 1, Room Gold 1 May 21-23 World Stem Cells and Regenerative Medicine Congress, Victoria Park Plaza, London, UK Presenter: Eduardo Bravo, CEO Date & time: Monday, May 21, 15:25 -15:50 Title: Cell Therapy & Regenerative Medicine – Progressing into phase III with an orphan indication May 24 Knowledge for Growth, ICC Ghent, Belgium Presenter: Eduardo Bravo, CEO Time: 11:30 Keynote speech – Advanced therapies: this time it is for real June 5-8 18th International Stem Cell Therapy Sociey Annual Meeting, Sheraton Seattle, WA, U.S. Continue reading
(SACRAMENTO, Calif.) — UC Davis Health System researchers are a step closer to launching human clinical trials involving the use of an innovative stem cell therapy to fight the virus that causes AIDS. In a paper published in the May issue of the Journal of Virology, the UC Davis HIV team demonstrated both the safety and efficacy of transplanting anti-HIV stem cells into mice that represent models of infected patients. The technique, which involves replacing the immune system with stem cells engineered with a triple combination of HIV-resistant genes, proved capable of replicating a normally functioning human immune system by protecting and expanding HIV-resistant immune cells. Continue reading
The American Society of Gene & Cell Therapy (ASGCT) will highlight the emergence of the latest in Parkinson’s disease treatments during its 15th Annual Meeting taking place in Philadelphia, Pennsylvania May 16 – 19, 2012.Milwaukee, WI (PRWEB) May 03, 2012 The American Society of Gene & Cell Therapy (ASGCT) will highlight the emergence of the latest in Parkinson’s disease treatments during its … Continue reading
PHILADELPHIA HIV patients treated with genetically modified T cells remain healthy up to 11 years after initial therapy, researchers from the Perelman School of Medicine at the University of Pennsylvania report in the new issue of Science Translational Medicine. The results provide a framework for the use of this type of gene therapy as a powerful weapon in the treatment of HIV, cancer, and a wide variety of other diseases Continue reading
ScienceDaily (May 2, 2012) HIV patients treated with genetically modified T cells remain healthy up to 11 years after initial therapy, researchers from the Perelman School of Medicine at the University of Pennsylvania report in the new issue of Science Translational Medicine. Continue reading
Public release date: 2-May-2012 [ | E-mail | Share ] Contact: Holly Auer holly.auer@uphs.upenn.edu 215-200-2313 University of Pennsylvania School of Medicine PHILADELPHIA — HIV patients treated with genetically modified T cells remain healthy up to 11 years after initial therapy, researchers from the Perelman School of Medicine at the University of Pennsylvania report in the new issue of Science Translational Medicine. The results provide a framework for the use of this type of gene therapy as a powerful weapon in the treatment of HIV, cancer, and a wide variety of other diseases. “We have 43 patients and they are all healthy,” says senior author Carl June, MD, a professor of Pathology and Laboratory Medicine at Penn Medicine. Continue reading
